Fabienne Hermitte

1.7k total citations
32 papers, 1.1k citations indexed

About

Fabienne Hermitte is a scholar working on Oncology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Fabienne Hermitte has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 7 papers in Surgery and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Fabienne Hermitte's work include Cancer Immunotherapy and Biomarkers (16 papers), Colorectal Cancer Treatments and Studies (10 papers) and Genetic factors in colorectal cancer (7 papers). Fabienne Hermitte is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Colorectal Cancer Treatments and Studies (10 papers) and Genetic factors in colorectal cancer (7 papers). Fabienne Hermitte collaborates with scholars based in France, Belgium and Italy. Fabienne Hermitte's co-authors include Patrice Viens, Daniel Birnbaum, François Bertucci, Pascal Finetti, Nathalie Cervera, Benjamin Esterni, Sarah B. Daly, Hans Beier Ommen, Claude Preudhomme and Enrico Gottardi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Fabienne Hermitte

32 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fabienne Hermitte France 11 550 433 357 310 179 32 1.1k
Ellen Geerdens Belgium 16 216 0.4× 438 1.0× 146 0.4× 315 1.0× 337 1.9× 17 970
Frank J. Godinho United States 7 193 0.4× 431 1.0× 250 0.7× 296 1.0× 106 0.6× 12 849
Phoenix A. Ho United States 15 259 0.5× 550 1.3× 176 0.5× 876 2.8× 351 2.0× 29 1.2k
Rhonda E. Ries United States 16 184 0.3× 605 1.4× 183 0.5× 652 2.1× 174 1.0× 105 1.0k
Lurdes Zamora Spain 13 271 0.5× 280 0.6× 110 0.3× 328 1.1× 71 0.4× 55 824
Jane E. Churpek United States 18 161 0.3× 360 0.8× 241 0.7× 621 2.0× 181 1.0× 45 1.1k
Ann‐Kathrin Eisfeld United States 19 133 0.2× 519 1.2× 303 0.8× 563 1.8× 145 0.8× 64 1.0k
Afua A. Mensah Switzerland 15 173 0.3× 638 1.5× 101 0.3× 309 1.0× 67 0.4× 30 931
Nicolas Goardon France 16 160 0.3× 470 1.1× 223 0.6× 249 0.8× 63 0.4× 29 905
Kourong Miao China 17 260 0.5× 560 1.3× 385 1.1× 202 0.7× 49 0.3× 79 1.1k

Countries citing papers authored by Fabienne Hermitte

Since Specialization
Citations

This map shows the geographic impact of Fabienne Hermitte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabienne Hermitte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabienne Hermitte more than expected).

Fields of papers citing papers by Fabienne Hermitte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabienne Hermitte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabienne Hermitte. The network helps show where Fabienne Hermitte may publish in the future.

Co-authorship network of co-authors of Fabienne Hermitte

This figure shows the co-authorship network connecting the top 25 collaborators of Fabienne Hermitte. A scholar is included among the top collaborators of Fabienne Hermitte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabienne Hermitte. Fabienne Hermitte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kassambara, Alboukadel, et al.. (2022). Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring. Cancers. 14(5). 1170–1170. 6 indexed citations
2.
Ottaiano, Alessandro, Michele Caraglia, Annabella Di Mauro, et al.. (2020). Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. Cancers. 12(10). 3073–3073. 24 indexed citations
3.
Galon, Jérôme, Fabienne Hermitte, Bernhard Mlecnik, et al.. (2020). Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients.. Journal of Clinical Oncology. 38(15_suppl). 4105–4105. 4 indexed citations
4.
Sinicrope, Frank A., Qian Shi, Fabienne Hermitte, et al.. (2020). Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectrum. 4(3). pkaa023–pkaa023. 32 indexed citations
5.
Ijsselsteijn, Marieke E., Rebeca Sanz‐Pamplona, Fabienne Hermitte, & Noel F.C.C. de Miranda. (2019). Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. Molecular Aspects of Medicine. 69. 123–129. 29 indexed citations
6.
Galon, Jérôme, Fabienne Hermitte, Bernhard Mlecnik, et al.. (2019). Significant differences in outcome between Immunoscore categories in stage I colon cancer patients. Annals of Oncology. 30. iv134–iv134. 3 indexed citations
7.
Galon, Jérôme, Fabienne Hermitte, Bernhard Mlecnik, et al.. (2019). Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.. Journal of Clinical Oncology. 37(4_suppl). 487–487. 16 indexed citations
8.
Mirghani, H., Bernhard Mlecnik, Fabienne Hermitte, et al.. (2019). High immunoscore is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced head and neck cancer patients. Annals of Oncology. 30. v452–v452. 4 indexed citations
9.
Pagès, Franck, Thierry André, Julien Taı̈eb, et al.. (2019). Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).. Journal of Clinical Oncology. 37(15_suppl). 3513–3513. 7 indexed citations
10.
Marabelle, Aurélien, Jean‐François Baurain, Ahmad Awada, et al.. (2019). Abstract CT069: A Phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma. Cancer Research. 79(13_Supplement). CT069–CT069. 2 indexed citations
11.
Shi, Qian, Fabienne Hermitte, Erica N. Heying, et al.. (2017). Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). Annals of Oncology. 28. iii153–iii153. 1 indexed citations
12.
Hermitte, Fabienne. (2016). Biomarkers immune monitoring technology primer: Immunoscore® Colon. Journal for ImmunoTherapy of Cancer. 4(1). 57–57. 33 indexed citations
13.
Giusiano, Sophie, Christine Formisano‐Tréziny, N Maroc, et al.. (2009). Development of a biochip‐based assay integrated in a global strategy for identification of fusion transcripts in acute myeloid leukemia: a work flow for acute myeloid leukemia diagnosis. International Journal of Laboratory Hematology. 32(4). 398–409. 4 indexed citations
14.
Bertucci, François, J M Le Doussal, Daniel Birnbaum, et al.. (2009). Prognostic value of the genomic grade index (GGi) as compared to centrally measured Ki-67 IHC and mitotic index in early breast cancer patients. Journal of Clinical Oncology. 27(15_suppl). 11094–11094. 1 indexed citations
15.
Bertucci, François, Pascal Finetti, Nathalie Cervera, et al.. (2008). How basal are triple‐negative breast cancers?. International Journal of Cancer. 123(1). 236–240. 365 indexed citations
16.
Ramsden, Simon, Sarah B. Daly, Wolf‐Jochen Geilenkeuser, et al.. (2006). EQUAL-quant: An International External Quality Assessment Scheme for Real-Time PCR. Clinical Chemistry. 52(8). 1584–1591. 36 indexed citations
17.
Gottardi, Enrico, Daniela Cilloni, Sarah B. Daly, et al.. (2005). Standardization of WT1 mRNA Quantification for Minimal Residual Disease (MRD) Monitoring in Acute Leukemia Patients: A European LeukemiaNet Concerted Action.. Blood. 106(11). 3295–3295. 2 indexed citations
18.
Birnbaum, Daniel, Patrice Viens, Jocelyne Jacquemier, et al.. (2004). Breast Cancer ProfileChip: from large scale gene expression profiling to oncodiagnostic device. European Journal of Cancer Supplements. 2(3). 99–99. 2 indexed citations
19.
Bertucci, François, Christophe Ginestier, Emmanuelle Charafe‐Jauffret, et al.. (2004). Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene. 23(14). 2564–2575. 101 indexed citations
20.
Maroc, N, Emmanuel Beillard, Julien Mozziconacci, et al.. (2004). A diagnostic biochip for the comprehensive analysis of MLL translocations in acute leukemia. Leukemia. 18(9). 1522–1530. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellen Geerdens Breakdown of academic impact, for papers by Frank J. Godinho Breakdown of academic impact, for papers by Phoenix A. Ho Breakdown of academic impact, for papers by Rhonda E. Ries Breakdown of academic impact, for papers by Lurdes Zamora Breakdown of academic impact, for papers by Jane E. Churpek Breakdown of academic impact, for papers by Ann‐Kathrin Eisfeld Breakdown of academic impact, for papers by Afua A. Mensah Breakdown of academic impact, for papers by Nicolas Goardon Breakdown of academic impact, for papers by Kourong Miao
Rankless by CCL
2026